Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and... Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Mehr anzeigen
INOVIO Announces Pricing of $30 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa., Dec. 13, 2024 PLYMOUTH MEETING, Pa., Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq:...
INOVIO Announces Proposed Public Offering PR Newswire PLYMOUTH MEETING, Pa., Dec. 12, 2024 PLYMOUTH MEETING, Pa., Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a...
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial PR Newswire PLYMOUTH MEETING...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Nov. 29, 2024 PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING, Pa., Nov. 14, 2024 New immunology data for INO-3107 supporting proposed mechanism...
Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 1.6393442623 | 1.83 | 1.96 | 1.75 | 1025377 | 1.82616243 | CS |
| 4 | -2.24 | -54.6341463415 | 4.1 | 4.4383 | 1.74 | 1532877 | 2.324511 | CS |
| 12 | -3.53 | -65.4916512059 | 5.39 | 5.83 | 1.74 | 711937 | 3.1415163 | CS |
| 26 | -6.72 | -78.3216783217 | 8.58 | 12.33 | 1.74 | 496609 | 4.88736072 | CS |
| 52 | -4.14 | -69 | 6 | 14.748 | 1.74 | 919552 | 7.82911881 | CS |
| 156 | -58.5 | -96.9184890656 | 60.36 | 63.24 | 1.74 | 3916808 | 18.65672459 | CS |
| 260 | -38.82 | -95.4277286136 | 40.68 | 426 | 1.74 | 9048036 | 122.73947816 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
